WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry

Saturday, August 23, 2008 General News J E 4
SHANGHAI, China, Aug. 22 WuXi PharmaTech (NYSE: WX),a leading pharmaceutical, biotechnology and medical device research anddevelopment outsourcing company with operations in China and the United States,today announced that it has promoted Dr. Rujian Ma to Vice President ofSynthetic Chemistry.

(Logo: )

Dr. Ma will report directly to Dr. Shuhui Chen, Chief Scientific Officerof WuXi PharmaTech.

"I am very delighted to promote Dr. Ma to this new leadership position. Dr.Ma's depth of synthetic chemistry experience and his commitment and coachingcapabilities of our young scientists undoubtedly will further accelerate thedevelopment of our core synthetic chemistry division. His new assignment willalso help us continually improve our service quality and productivity and toserve our customers better." commented Dr. Shuhui Chen, Chief ScientificOfficer of WuXi PharmaTech.

Dr. Ma received his Ph.D. in Organic Chemistry from the University ofTokushima, Japan and joined in WuXi in March 2001.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medicaldevice R&D outsourcing company, with operations in China and the United States.As a research-driven and customer-focused company, WuXi PharmaTech providespharmaceutical, biotechnology and medical device companies a broad andintegrated portfolio of laboratory and manufacturing services throughout thedrug and medical device R&D process. WuXi PharmaTech's services are designedto assist its global partners in shortening the cycle and lowering the cost ofdrug and medical device R&D. For more information, please visit: .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002


SOURCE WuXi PharmaTech (Cayman) Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Regenesis Biomedical Announces Additions to Board ...
BioForm Medical to Announce Financial Results for ...